• Drugs Made in America Acquisition II posted net income of USD 4.2 million for fiscal 2025, driven by USD 4.9 million of interest earned on cash and investments held in the trust account.
• Revenue was not reported, as the SPAC had not generated operating revenues to date.
• General and administrative costs totaled USD 488,385, while a USD 812,113 provision for credit losses reflected a full reserve against amounts due from the sponsor.
• Cash on hand was USD 223 at year-end, with a working capital deficit of USD 274,827.
• Management said conditions raised substantial doubt about its ability to continue as a going concern within one year after the financial statements are issued.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-044055), on April 15, 2026, and is solely responsible for the information contained therein.